• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Is Roche's pRED fi­nal­ly ready to step out from be­hind Genen­tech for its close­up? Prob­a­bly not

8 years ago
Bioregnum
R&D

Shire hit by a set­back as Hunter syn­drome drug fails late-stage study

8 years ago
R&D

Step­ping up be­hind Sanofi, Genen­tech rolls the DiCE on a new small mol­e­cule dis­cov­ery pact

8 years ago
Pharma

Aerie bags an ear­ly OK for its self-de­scribed block­buster glau­co­ma drug Rho­pres­sa, re­cruit­ing 100 reps

8 years ago
Pharma

Apo­tex founder and wife's death now sus­pect­ed homi­cide; Spec­trum CEO Ra­jesh Shrotriya fired

8 years ago
News Briefing

On a new deal spree, Re­gen­eron buys in­to ISA in pur­suit of a check­point com­bo

8 years ago
Pharma

Se­vere job cuts at Te­va in­cite mas­sive work­er strikes, shut­ting Is­rael down

8 years ago
R&D
Pharma

What’s the big hur­ry, No­var­tis? Phar­ma gi­ant scores a PRV short­cut for $130M

8 years ago
Pharma

Al­ler­gan and Gedeon Richter ready to knock on FDA's door af­ter a pos­i­tive PhI­II for cariprazine in bipo­lar de­pres­sion

8 years ago
R&D

Ab­b­Vie vet John Leonard moves up to the helm at CRISPR/Cas9 pi­o­neer In­tel­lia, fo­cused on loom­ing hu­man stud­ies

8 years ago
People

Boehringer antes up on a €627.5M deal for rights to Au­ti­fony’s schiz­o­phre­nia drugs

8 years ago
Pharma

Bain leads big $70M round as Aptinyx plunges deep­er in­to NM­DA work

8 years ago
Financing

Andy Boy­er joins Te­va ex­o­dus; Achao­gen shuf­fles ex­ec­u­tive line­up

8 years ago
Peer Review

Cel­gene forges can­cer pact with CRT; FDA OKs Pfiz­er's Xel­janz as treat­ment for pso­ri­at­ic arthri­tis

8 years ago
News Briefing

Four months af­ter pa­tient death, FDA's hold lift­ed on Al­ny­lam's fi­tusir­an

8 years ago
Pharma

The 50 most ac­tive biotech VC funds in 2017

8 years ago
Financing

Am­i­cus CEO lob­bied FDA to re­verse FDA’s re­jec­tion of mi­gala­s­tat, claim­ing a de­lay of up to 7 years

8 years ago
Pharma

Grail taps Genen­tech vet Jen­nifer Cook as CEO, build­ing ex­pec­ta­tions for 2018

8 years ago
People
Peer Review

No­var­tis on­col­o­gy CEO Bruno St­rig­i­ni is call­ing it quits

8 years ago
People
Peer Review

One of Mer­ck­'s piv­otal stom­ach can­cer tri­als for Keytru­da flops, just months af­ter an FDA OK

8 years ago
R&D

Gala­pa­gos snags co-pro­mo­tion rights on fil­go­tinib — just be­fore Gilead’s lock-up pact ex­pires

8 years ago
R&D
Pharma

Jnana launch­es with $50M to spot­light an un­ex­plored pro­tein ter­ri­to­ry

8 years ago
Financing
Startups

Pfiz­er's Ix­i­fi gets ap­proved as third Rem­i­cade biosim­i­lar; No­vo Nordisk li­cens­es re­MYN­D's di­a­betes pro­gram in ...

8 years ago
News Briefing

Bris­tol-My­ers teams up with Op­di­vo mak­er Ono Phar­ma­ceu­ti­cal on new I/O pro­grams

8 years ago
R&D
Pharma
First page Previous page 1077107810791080108110821083 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times